[Biomarkers in endocrinology].
d'Herbomez M, Bauters C, Cortet-Rudelli C, Dewailly D, Docao C, Wémeau JL.
Presse Med. 2014 Jan;43(1):40-56. doi: 10.1016/j.lpm.2013.11.003. Epub 2013 Dec 15.
Hypercalcitoninaemia in medullary carcinoma of the thyroid and other malignancies: value of calcitonin as tumour marker.
Marrinan M, Skrabanek P, Moriarty M, McPartlin J, Powell D.
Horm Metab Res. 1982 Apr;14(4):213-5. doi: 10.1055/s-2007-1018972.
Gallium-68 Dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin.
Tran K, Khan S, Taghizadehasl M, Palazzo F, Frilling A, Todd JF, Al-Nahhas A.
Hell J Nucl Med. 2015 Jan-Apr;18(1):19-24. doi: 10.1967/s002449910163. Epub 2015 Feb 13.
The syndrome of excessive thyrocalcitonin produced by medullary carcinoma of the thyroid.
Melvin KE, Tashjian AH Jr.
Proc Natl Acad Sci U S A. 1968 Apr;59(4):1216-22. doi: 10.1073/pnas.59.4.1216.
Long-term excess of endogenous calcitonin in patients with medullary thyroid carcinoma does not affect bone mineral density.
Wüster C, Raue F, Meyer C, Bergmann M, Ziegler R.
J Endocrinol. 1992 Jul;134(1):141-7. doi: 10.1677/joe.0.1340141.
Medullary thyroid carcinoma and calcitonin.
Emmertsen K.
Dan Med Bull. 1985 Mar;32(1):1-28.
"Aging bull'.
Geelhoed GW.
Med Hypotheses. 1996 Dec;47(6):471-9. doi: 10.1016/s0306-9877(96)90160-7.
Calcitonin: physiology or fantasy?
Davey RA, Findlay DM.
J Bone Miner Res. 2013 May;28(5):973-9. doi: 10.1002/jbmr.1869.
Thyroid nodules: alpha guide to assessment, treatment and follow-up.
Paschou SA, Vryonidou A, Goulis DG.
Maturitas. 2017 Feb;96:1-9. doi: 10.1016/j.maturitas.2016.11.002. Epub 2016 Nov 9.
Excessive L-thyroxine therapy decreases femoral bone mineral densities in the male rat: effect of hypogonadism and calcitonin.
Ongphiphadhanakul B, Alex S, Braverman LE, Baran DT.
J Bone Miner Res. 1992 Oct;7(10):1227-31. doi: 10.1002/jbmr.5650071015.
